

# Financial Tear Sheet

## Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of dimethyl fumarate (DMF) for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.

## Stock Performance

### FWP (Common Stock)

**Exchange** NASDAQ GS (US Dollar)

**Financial Status Indicator** C

**Price** **\$4.73**

**Change (%)** ▲ 0.45 (10.51%)

**Volume** 11,864

**52 Week Low** \$2.70

**Market Cap** \$223,180,315

**Rolling EPS** 3.80

**PE Ratio** 1.1257

**Shares Outstanding** 47,183,999

Data as of 11/17/17 4:00 p.m. ET



## Recent Headlines

11/09/17

Forward Pharma to Participate in the Nordic-American Life Science Conference

---

09/26/17

Forward Pharma Reports Financial and Operational Results from the First Six Months of 2017

---

09/05/17

Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit

---

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

<b>Filing Date</b>	<b>Form</b>
11/03/17	6-K
10/02/17	6-K
09/26/17	6-K
09/11/17	6-K

## Corporate Governance

Claus Bo Svendsen, MD, PhD	CEO
Peder Møller Andersen, MD	COO

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*